Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 6.72B 6B 5.51B 5.01B 9.4B 636B 9.64B 65.8B 26.47B 336B 25.21B 24.67B 1,064B P/E 2026 *
-11.4x
P/E 2027 * -20.7x
Enterprise Value 6.61B 5.91B 5.43B 4.93B 9.26B 627B 9.49B 64.79B 26.06B 331B 24.83B 24.3B 1,048B EV / Sales 2026 *
7.17x
EV / Sales 2027 * 4.99x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.99%
1 week-8.05%
Current month-7.12%
1 month-7.17%
3 months-25.82%
6 months-46.31%
Current year-48.91%
1 week 40.26
Extreme 40.26
45.84
1 month 40.26
Extreme 40.26
45.84
Current year 40.26
Extreme 40.26
86.74
1 year 40.26
Extreme 40.26
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Others

Chief Technology Officer

110 0.0001%
8/31/26 Others

Executive/Senior Manager

58 0.0000%
8/31/26 Others

Founder

98 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%-8.05%-45.12%-14.35% 6.72B
-2.43%-4.38%+40.32%+55.64% 60.57B
+0.62%+2.58%+20.96%+98.18% 55.51B
+0.61%+0.77%+11.13%+69.42% 55.22B
+1.61%-3.30%+22.77%+33.16% 43.27B
-1.74%-3.02%+13.83%+93.17% 40.36B
+3.22%+4.30%+227.37%+776.49% 41.63B
+0.57%+24.09%+99.46%+84.11% 33.29B
-1.09%+0.69%+14.20%+45.26% 32.27B
-4.46%+9.98%-43.92%+320.28% 22.91B
Average -0.51%+2.24%+36.10%+156.13% 39.17B
Weighted average by Cap. -0.20%+1.98%+45.15%+157.44%

Financials

2026 *2027 *
Net sales 922M 824M 757M 687M 1.29B 87.37B 1.32B 9.04B 3.63B 46.12B 3.46B 3.39B 146B 1.36B 1.21B 1.12B 1.01B 1.9B 129B 1.95B 13.32B 5.36B 67.99B 5.1B 5B 216B
Net income -579M -518M -475M -432M -811M -54.88B -831M -5.68B -2.28B -28.97B -2.17B -2.13B -91.81B -327M -292M -269M -244M -458M -31.01B -470M -3.21B -1.29B -16.37B -1.23B -1.2B -51.87B
Net Debt -103M -92.01M -84.52M -76.76M -144M -9.76B -148M -1.01B -406M -5.15B -387M -378M -16.32B 68.31M 61.03M 56.06M 50.91M 95.61M 6.47B 98.01M 669M 269M 3.42B 256M 251M 10.82B
Projected Income Statement - Annual - Ionis Pharmaceuticals, Inc.
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
26-11-03 US$40.42 -1.99% 4,006,909
26-11-02 US$41.24 -5.24% 2,559,959
26-10-30 US$43.52 -1.96% 1,522,192
26-10-29 US$44.39 -1.14% 1,833,848
26-10-28 US$44.90 +2.14% 1,724,370
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Ionis Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
40.42USD
Average target price
84.13USD
Spread / Average Target
+108.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ionis Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. IONS Stock